問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
吳宗翰
下載
2019-05-01 - 2029-12-31
Condition/Disease
Test Drug
Participate Sites6Sites
Recruiting3Sites
Terminated3Sites
2020-03-01 - 2028-12-31
Participate Sites8Sites
Recruiting8Sites
2024-03-01 - 2026-03-31
Participate Sites3Sites
Recruiting2Sites
Terminated1Sites
2021-03-01 - 2026-12-30
Recruiting6Sites
2022-01-01 - 2026-12-31
2018-09-01 - 2022-12-31
Hepatocellular Carcinoma (HCC)
nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞
Participate Sites9Sites
2023-04-12 - 2028-04-12
Participate Sites1Sites
Recruiting1Sites
2019-11-30 - 2024-07-31
Advanced Hepatocellular Carcinoma
OPDIVO (nivolumab) Injection 10mg/mLOPDIVO (nivolumab) Injection 10mg/mLYERVOY (ipilimumab) Injection 5mg/mLYERVOY (ipilimumab) Injection 5mg/mL
Recruiting9Sites
全部
